Prevalence and Prognostic Impact of Non-Cardiac Co-Morbidities in Heart Failure Outpatients with Preserved and Reduced Ejection Fraction: A Community-Based Study
Andrea Di Lenarda(University of Trieste), Giulia Barbati(University of Trieste), Luigi Tarantini(Santa Maria Nuova Hospital), Gianfranco Sinagra(Società Italiana di Cardiologia), Antonello Gavazzi(Ospedale Papa Giovanni XXIII), Michele Senni(Inserm), Giovanni Cioffi(Casa di Cura Villa Bianca), Concetta Di Nora(University of Trieste), Stefano Poli(University of Trieste), Stephen J. Greene(Duke Medical Center), Elena Zambon(University of Trieste)
Cited by 174
Related Papers
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
The Global Health and Economic Burden of Hospitalizations for Heart Failure
|Journal of the American College of Cardiology|2014|2k
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
|The Lancet|2018|1.8k
Truncations of Titin Causing Dilated Cardiomyopathy
|New England Journal of Medicine|2012|1.5k
Medical Therapy for Heart Failure With Reduced Ejection Fraction
|Journal of the American College of Cardiology|2018|1.3k